Vedana Therapeutics
Seattle, Washington, United StatesSee on the mapFounded 2024
- Series A
Vedana Therapeutics is a biotechnology company advancing therapeutic antibody programs. Its team supports the development of mono- and multispecific antibodies from discovery and protein engineering through preclinical development and preparation for first-in-human studies.
- RaisedTotal raised
- $46M
- Jun 2026Latest priced round, Jun 2026
- Series A
- Investors
- 4
- Founded
- 2024
- Employees
- 11–50
reccy insights
Vedana Therapeutics’ clearest disclosed milestone is its $46 million Series A, announced on Jun 17, 2026. The round lists Canaan Partners, Westlake Village BioPartners, Alexandria Venture Investments, and Dawn Biopharma among its investors. The financing gives the Seattle-based company capital to advance its therapeutic antibody work, although specific funded programs, spending plans, and development timelines have not been disclosed. Founded in 2024, Vedana is developing preventive migraine therapies and describes capabilities spanning antibody discovery, protein engineering, pharmacology, bioanalysis, and preclinical development. Its stated scope includes monoclonal and multispecific antibody programs, with work intended to progress from discovery toward first-in-human preparation. The available details therefore point to a financing and platform-building phase rather than a publicly documented clinical or commercial inflection point.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes Vedana Therapeutics distinct
- 01Combines expertise in antibody discovery, protein sciences, pharmacology, bioanalysis, and program management.
- 02Team experience spans biologics development from discovery through preclinical work, IND-enabling activities, and clinical development.
- 03Works across both monoclonal and multispecific antibody programs.
- 04Leadership and scientific experience includes biotechnology companies such as Alder Biopharmaceuticals, Amgen, Aptevo Therapeutics, and Regeneron.
Technology & products
- Therapeutic antibody discovery and development
- Monoclonal and multispecific antibody programs
- Protein engineering and antibody optimization
- Preclinical pharmacology and bioanalytical assay development
Recent updates1
- Jun 17, 2026Product launch
Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies
businesswire.com
Funding
- Series AJun 2026$46MLed by Canaan Partners, Westlake Village BioPartners, Alexandria Venture Investments, Dawn Biopharma
Investors4
- Canaan Partners
- Westlake Village BioPartners
- Dawn Biopharma
About Vedana Therapeutics
- Leadership
- Anurag AgarwalLeon Martinez
- Focus areas
- Biotechnology, therapeutics, antibodies, biologics, drug discovery, protein engineering, preclinical development, immuno oncology
- Headquarters
- Seattle, Washington, United States
- Founded
- 2024
- Employees
- 11–50
- Status
- Active · private